Rajalu Banu Manickam, Jayarajan Deepak, Muliyala Krishna Prasad, Sharma Priyamvada, Gandhi Sailaxmi, Chand Prabhat Kumar, Thirthalli Jagadisha, Murthy Pratima
Psychiatric Rehabilitation Services, National Institute of Mental Health and Neurosciences, Bangalore, 560029, India.
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, 560029, India.
Asian J Psychiatr. 2021 Feb;56:102530. doi: 10.1016/j.ajp.2020.102530. Epub 2021 Jan 14.
The rates and intensity of tobacco use are higher in persons with schizophrenia spectrum disorders (PwS) compared to the general population, contributing to increased morbidity and mortality. We aimed to systematically review randomised control trials (RCTs) that used non-pharmacological interventions to reduce or cease tobacco use in PwS.
We searched PubMed, EBSCO, ProQuest and PsycINFO for RCTs, published between January 2004 and December 2019, which included adult PwS. Studies providing self-reported or biochemically measured reduction of tobacco use and cessation after a minimum follow-up period of 6 months were included. We used the Cochrane Risk of Bias (ROB) tool for assessing the quality of selected studies.
Of the six included trials, two compared non-pharmacological interventions alone while four compared combinations with pharmacological interventions with routine care. The non-pharmacological interventions varied widely. Continuous abstinence and seven days point-prevalence abstinence (7 PPA) were reported in 2 and 4 studies respectively, with one study assessing both. All six trials measured reduction in the number of cigarettes smoked, but only two trials reported significant reductions in intervention groups. No worsening of psychiatric symptoms was reported.
Two trials were rated as "low risk", and 4 trials as "some concerns" on the ROB tool. Heterogeneity among trials precluded meta-analysis. Abstinence was significantly higher among groups who were given combination interventions, and intervention groups in studies showed significantly greater or a trend towards reduction in the number of cigarettes smoked than controls. No specific method of non-pharmacological management was conclusively favoured.
Reduction in cigarettes smoked seemed to significantly favour or show non-significant trends favouring intervention groups over controls, while abstinence was significantly higher among groups in studies that used specific combination interventions. Combinations of pharmacological and non-pharmacological treatment were better than non-pharmacological interventions used in isolation, for facilitating abstinence and reduction in cigarettes smoked. Specific interventions such as home visits and contingent reinforcement merit further study. Trials included in this study were conducted in high-income and upper-middle-income countries. Thus, the application of these interventions to low and middle-income countries (LAMICs) needs to be further studied.
与普通人群相比,精神分裂症谱系障碍患者(PwS)的烟草使用率和使用强度更高,这导致发病率和死亡率上升。我们旨在系统评价使用非药物干预措施来减少或戒除PwS烟草使用的随机对照试验(RCT)。
我们在PubMed、EBSCO、ProQuest和PsycINFO中检索了2004年1月至2019年12月发表的包含成年PwS的RCT。纳入的研究需提供自我报告或生化测量的烟草使用减少情况以及至少6个月随访期后的戒烟情况。我们使用Cochrane偏倚风险(ROB)工具来评估所选研究的质量。
在纳入的六项试验中,两项试验仅比较了非药物干预措施,而四项试验比较了药物干预与常规护理相结合的情况。非药物干预措施差异很大。分别有2项和4项研究报告了持续戒烟和7天点流行率戒烟(7 PPA)情况,其中一项研究对两者均进行了评估。所有六项试验都测量了吸烟量的减少,但只有两项试验报告干预组有显著减少。未报告精神症状恶化情况。
在ROB工具上,两项试验被评为“低风险”,四项试验被评为“有些担忧”。试验之间的异质性妨碍了荟萃分析。接受联合干预的组中戒烟率显著更高,且研究中的干预组与对照组相比,吸烟量减少显著或有减少趋势。没有一种非药物管理的特定方法得到明确支持。
吸烟量减少似乎显著有利于干预组或显示出有利于干预组而非对照组但不显著的趋势,而在使用特定联合干预措施的研究组中戒烟率显著更高。药物和非药物治疗相结合比单独使用非药物干预措施更有利于促进戒烟和减少吸烟量。家访和偶然强化等特定干预措施值得进一步研究。本研究纳入的试验是在高收入和中高收入国家进行的。因此,这些干预措施在低收入和中等收入国家(LAMICs)的应用需要进一步研究。